



OxySure (OXYS) Stockholders Vote in Favor of Uplisting Support

Frisco, Texas, September 17, 2015 – OxySure Systems, Inc. (OTCQB: OXYS) (OxySure, or the Company), the medical device innovator of life-saving easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other medical solutions, today announced that the Company’s stockholders voted to approve two proposals designed to support an uplisting of the Company to a national exchange such as Nasdaq and an amendment of the Company’s structure to facilitate significant future growth.

At the Company’s Special Meeting of Stockholders held on September 15, 2015, the Company’s stockholders voted on, and approved, two proposals, the final voting results of which are provided below:

Proposal No. 1 – Reverse Stock Split. The Company’s stockholders approved the proposal to authorize an amendment to the Company’s Articles of Incorporation to effect a reverse stock split of our common stock, par value \$0.0004, at a specific ratio, within a range of 1-for-2 and 1-for-100 shares, to be determined by our Board of Directors in its sole discretion and effected, if at all, within one year from the date of the Special Meeting.

For	Against	Abstain
17,897,811	284,113	17,320

Proposal No. 2 – Increase in Authorized Shares. The Company’s stockholders approved the proposal to authorize an amendment to the Company’s Articles of Incorporation to increase the authorized shares of the Company’s common stock, par value \$0.0004, from 100,000,000 shares to 500,000,000 shares.

For	Against	Abstain
17,589,101	407,643	202,500

“We are very pleased to have our stockholders’ support in pursuing our uplisting and growth goals,” said Julian Ross, OxySure’s CEO. “This step keeps us on track with our plans and we look forward to accelerating things as we move through the final phase of the process.”

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from two dry, inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of

amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

OxySure Contacts:

Renmark Financial Communications, Inc.
Bettina Filippone: bfilippone@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com/

Redchip Companies, Inc.
Jon Cunningham: jon@redchip.com
800-733-2447, ext. 107 | www.redchip.com/